HT BioImaging
Tel Aviv, Israel· Est.
HT BioImaging delivers AI‑powered heat‑diffusion scans for rapid, point‑of‑care cancer detection in humans and animals.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
HT BioImaging delivers AI‑powered heat‑diffusion scans for rapid, point‑of‑care cancer detection in humans and animals.
Oncology
Technology Platform
Heat Diffusion Imaging (HDI) uses a focused thermal pulse and AI‑enhanced signal analysis to map tissue heat diffusion, producing high‑resolution probability maps of cancerous lesions.
Opportunities
Expansion into point‑of‑care settings worldwide and integration with AI‑driven health‑record platforms could unlock multi‑billion‑dollar market potential.
Risk Factors
Regulatory clearance beyond oral cancer, reimbursement acceptance, and competition from established imaging modalities pose significant execution risks.
Competitive Landscape
HT BioImaging differentiates from MRI, PET, and optical imaging by offering a rapid, non‑radiative, AI‑enhanced heat‑diffusion scan, though it must compete with entrenched diagnostic technologies.